However, some may take it off-label (meaning for a use the FDA has not approved) to treat bipolar disorder. Various studies ...

The most important step is to reach out for help from mental health or medical professionals in order to receive support in ...

Explore hyposexuality in bipolar disorder, including symptoms like low libido, reduced sexual desire, and difficulty ...

Discover real experiences from our bipolar community on the potential benefits and challenges of ketogenic therapy for mood ...

The U. S. Food and Drug Administration (FDA) has signed off on Cobenfy, the first revolutionary treatment for schizophrenia ...

. Increasing Prevalence: The lifetime prevalence of bipolar disorder is estimated at 1%, with a one-year prevalence of about 0.5% globally. The rise in diagnoses is attributed to greater awareness and ...

RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine ...

“Among the millions of people in the U.S. suffering from the debilitating effects of depression, more than half experience an inadequate response to their current antidepressant, underscoring the ...

Deakin Distinguished Professor Michael Berk has been named a recipient of the 2024 Australian Mental Health Prize in ...

Four Australians have been recognised, including a researcher who’s created an equine therapy program for Aboriginal youth ...

Teva Pharma announces long term efficacy and safety of deutetrabenazine in European patients with debilitating movement disorder tardive dyskinesia: Tel Aviv, Israel Tuesday, Sept ...

Ahead of ADHD Awareness Month, Busy is sharing her ADHD diagnosis and Qelbree® (viloxazine extended-release capsules) treatment story to empower ...